Acerus currently has licensed marketing partners in over 71 countries, including Canada, and working to diversify revenue across meaningful markets globally.
Acerus continues to pursue business development opportunities that align with our therapeutic focus in Men’s Health (Urology and Andrology). However, we are open to consideration of opportunities in other complimentary therapeutic areas.
We also have an interest in partnership with third parties in jurisdictions outside of Canada that have the requisite expertise in marketing pharmaceutical products, as well as sufficient resources to effectively commercialize our products at a favourable value inflection point for each of our pipeline programs.
Become a Partner
Acerus offers in-house expertise at all stages of the pharmaceutical product lifecycle, from clinical and regulatory competency to full commercialization capabilities.
For more information on partnership opportunities with Acerus, please contact us at BD@aceruspharma.com.
Acerus currently has partnerships in the following regions for the Licensed Brand Natesto®
- Signed
- Filing Under Prep.
- Submitted For Review*
- Approved
Partner
(Logos) |
Partner
(Name) |
Region |
Licensed Brand |
Status |
 |
Aytu
Biosciences |
United States |
NATESTO® |
Approved |
 |
Hyundai |
South Korea |
NATESTO® |
Approved |
 |
Medac |
28 current EU member countries (including the United Kingdom) as well as Norway, Liechtenstein, Iceland, Turkey (including Turkish Cyprus), Australia, New Zealand, Israel and South Africa |
NATESTO® |
Submitted for Review* |
 |
Carnot |
Mexico |
NATESTO® |
Filing under prep. |
|
Carnot |
South America |
NATESTO® |
Filing under prep. |
 |
Apsen |
Brazil |
NATESTO® |
Filing under prep. |
 |
Therios |
Egypt, UAE and Saudi Arabia |
NATESTO® |
Filing under prep. |
| EU HWA |
EU HWA |
Asia Pacific |
NATESTO® |
Filing under prep. |
*First 21 EU countries under DCP. See our Press Release.